Journal Home
Search for

Volume 136, Issue 3, Pages 688-696 (September 2008)


View previous. 27 of 69 View next.

Aortic valve replacement with the Mitroflow pericardial bioprosthesis: Durability results up to 21 years

Charles A. Yankah, MD, PhDCorresponding Author Informationemail address, Miralem Pasic, MD, PhD, Michele Musci, MD, Julia Stein, MSc, Christine Detschades, SRN, Henryk Siniawski, MD, PhD, Roland Hetzer, MD, PhD

Received 12 November 2007; received in revised form 28 March 2008; accepted 13 May 2008. published online 14 July 2008.

Objective

The study aim was to analyze the performance profile of a large series of Mitroflow pericardial valves (Sorin Group Canada Inc. Mitroflow Division) in the very long term.

Methods

Data from 1513 patients with isolated aortic valve replacement who received pericardial bioprostheses between 1986 and 2007 were analyzed. Cumulative duration of follow-up was 6164 patient-years with a maximum duration of 21 years. Actuarial rates of valve-related events were calculated by the Kaplan–Meier method and the Cox multivariate analysis to identify independent determinants of outcome.

Results

Hospital mortality for elective surgery was 2.5%. Late death was 40.6%. Reoperation was required in 86 (5.7%) patients and was valve related in 83: structural valve deterioration in 64 (4.2%) patients, prosthetic valve endocarditis in 17 patients (1.1%), valve thrombosis in 1, and periprosthetic leak in 1. Rates of 20-year actuarial freedom from valve-related morbidity were as follows: structural valve deterioration 84.8% (actual 96.6%) in patients 70 years of age or older; thromboembolism 94.1%; and prosthetic valve endocarditis 96.8%. Twenty-year actual risk of reoperation for structural valve deterioration was 11.4% in all patients and 3.4%, in patients 70 years or age or older. Advanced age, renal insufficiency, pulmonary disease, and low body mass index were independent risk factors for late outcome (P < .001).

Conclusions

After 2 decades of follow-up, the Mitroflow pericardial aortic valve continues to be a valve of choice with a predictable low rate of valve-related events, particularly for patients over the age of 65 to 70 years and others with comorbidities.

CTSNet classification35

Deutsches Herzzentrum Berlin, Berlin, Germany

Corresponding Author InformationAddress for reprints: A. Charles Yankah, MD, PhD, Professor of Surgery, Humboldt, Charité Medical University, German Heart Institute Berlin, Augustenburger Platz 1, D-13353 Berlin, Germany.

 Charles Yankah reports consulting and lecture Fees From Sorin.

PII: S0022-5223(08)00876-3

doi:10.1016/j.jtcvs.2008.05.022


View previous. 27 of 69 View next.